Dmytro S Radchenko

Dr. Dmytro S Radchenko

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
CGChristoph Gorgulla
Christoph Gorgulla
ABAndras Boeszoermenyi
Andras Boeszoermenyi
ZWZi-Fu Wang
Zi-Fu Wang
PFPatrick D. Fischer
Patrick D. Fischer
PCPaul W. Coote
Paul W. Coote
HAHaribabu Arthanari
Haribabu Arthanari

15 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ASArman A. Sadybekov
Arman A. Sadybekov
ASAnastasiia Sadybekov
Anastasiia Sadybekov
YLYongfeng Liu
Yongfeng Liu
CIChristos Iliopoulos-Tsoutsouvas
Christos Iliopoulos-Tsoutsouvas
XHXi-Ping Huang
Xi-Ping Huang
Vsevolod KatritchVsevolod Katritch
Vsevolod Katritch

1 November 2020 in iScience
Verified
Journal Article
Open access
OGOleksandr Grygorenko
Oleksandr Grygorenko
DRDmytro S Radchenko
Dmytro S Radchenko
IDIgor Dziuba
Igor Dziuba
ACAlexander Chuprina
Alexander Chuprina
KGKateryna E. Gubina
Kateryna E. Gubina
YMYurii S. Moroz
Yurii S. Moroz
An approach to the generation of ultra-large chemical libraries of readily accessible (“REAL”) compounds is described. The strategy is based on the use of two- or three-step three-component reaction sequences and available starting materials with pre-validated chemical reactivity. After the preliminary parallel experiments, the methods with at least ∼80% synthesis success rate (such as acylation – deprotection – acylation of monoprotected diamines or amide formation – click reaction with functionalized azides) can be selected and used to generate the target chemical space. It is shown that by using only on the two aforementioned reaction sequences, a nearly 29-billion compound library is easily obtained. According to the predicted physico-chemical descriptor values, the generated chemical space contains large fractions of both drug-like and “beyond rule-of-five” members, whereas the strictest lead-likeness criteria (the so-called Churcher's rules) are met by the lesser part, which still exceeds 22 million.

8 December 2021 in Nature
Verified
Journal Article
Closed access
PDF file
AAAssaf Alon
Assaf Alon
JLJiankun Lyu
Jiankun Lyu
JBJoao M. Braz
Joao M. Braz
TTTia A. Tummino
Tia A. Tummino
VCVeronica Craik
Veronica Craik
AKAndrew C. Kruse
Andrew C. Kruse

4 January 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SGStefan Gahbauer
Stefan Gahbauer
GCGalen J. Correy
Galen J. Correy
MSMarion Schuller
Marion Schuller
MFMatteo P. Ferla
Matteo P. Ferla
YDYagmur Umay Doruk
Yagmur Umay Doruk
JFJames S. Fraser
James S. Fraser
The nonstructural protein 3 (NSP3) of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) contains a conserved macrodomain enzyme (Mac1) that is critical for pathogenesis and lethality. While small-molecule inhibitors of Mac1 have great therapeutic potential, at the outset of the COVID-19 pandemic, there were no well-validated inhibitors for this protein nor, indeed, the macrodomain enzyme family, making this target a pharmacological orphan. Here, we report the structure-based discovery and development of several different chemical scaffolds exhibiting low- to sub-micromolar affinity for Mac1 through iterations of computer-aided design, structural characterization by ultra-high-resolution protein crystallography, and binding evaluation. Potent scaffolds were designed with in silico fragment linkage and by ultra-large library docking of over 450 million molecules. Both techniques leverage the computational exploration of tangible chemical space and are applicable to other pharmacological orphans. Overall, 160 ligands in 119 different scaffolds were discovered, and 153 Mac1-ligand complex crystal structures were determined, typically to 1 Å resolution or better. Our analyses discovered selective and cell-permeable molecules, unexpected ligand-mediated conformational changes within the active site, and key inhibitor motifs that will template future drug development against Mac1.

18 October 2022 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
MKMaria Korshunova
Maria Korshunova
NHNiles Huang
Niles Huang
SCStephen Capuzzi
Stephen Capuzzi
DRDmytro S Radchenko
Dmytro S Radchenko
OSOlena Savych
Olena Savych
OIOlexandr Isayev
Olexandr Isayev
Deep generative neural networks have been used increasingly in computational chemistry for de novo design of molecules with desired properties. Many deep learning approaches employ reinforcement learning for optimizing the target properties of the generated molecules. However, the success of this approach is often hampered by the problem of sparse rewards as the majority of the generated molecules are expectedly predicted as inactives. We propose several technical innovations to address this problem and improve the balance between exploration and exploitation modes in reinforcement learning. In a proof-of-concept study, we demonstrate the application of the deep generative recurrent neural network architecture enhanced by several proposed technical tricks to design inhibitors of the epidermal growth factor (EGFR) and further experimentally validate their potency. The proposed technical solutions are expected to substantially improve the success rate of finding novel bioactive compounds for specific biological targets using generative and reinforcement learning approaches.